{
  "docId": "019dd923-5de0-76bd-a164-b717ba6950ff",
  "docSlug": "eb4f894ec6f4abbf",
  "documentTitle": "Medical Affairs Outlook Report 2023",
  "authorId": "ZS",
  "authorName": "ZS",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 12,
  "pageCount": 17,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a large photo of two professionals collaborating as a visual anchor for the findings.",
  "elementsJson": [
    "photo",
    "paragraph"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5de0-76bd-a164-b717ba6950ff/12",
  "deckHref": "/decks/019dd923-5de0-76bd-a164-b717ba6950ff",
  "deckJsonHref": "/decks/019dd923-5de0-76bd-a164-b717ba6950ff.json",
  "deckAnchorHref": "/decks/019dd923-5de0-76bd-a164-b717ba6950ff#slide-12",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "More than a third of mentions from external respondents indicated that they would like to collaborate with medical affairs organizations on clinical trials and research programs.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-edaa-73b9-9029-dbea361bf58c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 1,
        "x": 0,
        "y": 0
      },
      "kind": "image",
      "text": "Two professionals collaborating on a tablet",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f8c6e68-7265-4b8d-88e7-648068918d1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.21,
        "y": 0.64
      },
      "kind": "paragraph",
      "text": "KOLs also told us they take multiple factors into consideration when partnering with pharma companies on clinical trials. More than two-thirds of external respondents said the most important factor is product perception and the unmet need the product addresses, followed by interim clinical trial results. In addition, more than half of the external respondents consider prior collaboration experience with the company. Factors such as other drugs in the pipeline also play a key role, according to almost half of the external respondents.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c57a8246-cafc-44a2-8570-8fe5677e511d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.58,
        "x": 0.21,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "More than a third of mentions from external respondents indicated that they would like to collaborate with medical affairs organizations on clinical trials and research programs. They want medical affairs teams to organize cross-functional meetings, provide engagement avenues and share product and disease expertise.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffb87e69-a1d9-4b9f-97af-528ff17cca76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.58,
        "x": 0.21,
        "y": 0.8
      },
      "kind": "title",
      "text": "More than a third of mentions from external respondents indicated that they would like to collaborate with medical affairs organizations on clinical trials and research programs.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11b85773-6495-4d89-982d-1bd256ee69b0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "985ce4b5-38f7-4b5a-93be-2eec2b6ce8c9",
      "evidence": "More than a third of mentions from external respondents indicated that they would like to collaborate with medical affairs organizations on clinical trials and research programs.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 9,
      "beatId": "c525a5ef-3a99-4c51-8abc-eb5dad661dff",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The deck provides key takeaways and recommendations for medical affairs organizations, including prioritizing investments and collaborating with external stakeholders",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 14,
      "from": 10,
      "beatId": "ddd73dd8-76c8-4866-b638-a1b59773307b",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The deck provides data and statistics to support its recommendations, including survey results from internal and external respondents",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "fb6f3987-81f5-48cc-b7d0-39a0cd21772e",
      "evidence": "The deck presents a logical chain of ideas, starting with the situation overview and building towards key takeaways and recommendations",
      "position": 0,
      "objective": "Understand the engagement landscape and prioritize investments",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 15,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "dff223a3-dda3-48f8-a5dd-27a7371e6fe5",
      "evidence": "The deck implies that not prioritizing investments and adapting to changing engagement landscapes may result in missed opportunities",
      "position": 1,
      "objective": "Highlight the consequences of not adapting to changing engagement landscapes",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}